News

Deal Announcements

Adnexus Raises Series C Financing Round

Friday, August 10, 2007 5:00:00 AM PDT | VentureDeal Staff
WALTHAM, MA -- Pharmaceutical company Adnexus Therapeutics, Inc. said that it has received $15.5 million in new venture capital investment in its third round of institutional funding.

Adnexus' first product candidate, Angiocept (CT-322) is in Phase 1 clinical development in oncology in the United States.  The company also has a pipeline of other "Adnectin" products in preclinical research across a number of therapeutic areas.

Investors in the round were HBM BioVentures, Atlas Venture, Flagship Ventures, Polaris Venture Partners and Venrock Associates.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1